Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas’ lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas is running a global Phase 3 trial within IgAN and, if approved, aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT).
Addressing niche indications with high unmet medical needs, leveraging agile and cost-effective development and
commercialisation approaches, with the goal to deliver quality oriented and impactful solutions to patients in a timely fashion.
To effectively leverage internal cross competencies in a patient / disease centric manner, to address sustainable market opportunities in a cost-efficient manner thereby delivering quality oriented and impactful solutions to patients and creating value for all our stake holders.
Career site by Teamtailor